BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19484759)

  • 1. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study.
    Uygun V; Karasu GT; Ogunc D; Yesilipek A; Hazar V
    Pediatr Blood Cancer; 2009 Oct; 53(4):610-4. PubMed ID: 19484759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia.
    Ichikawa M; Suzuki D; Ohshima J; Cho Y; Kaneda M; Iguchi A; Ariga T
    Pediatr Blood Cancer; 2011 Dec; 57(7):1159-62. PubMed ID: 21438131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
    Zengin E; Sarper N; Kılıç SC
    Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.
    Karaman S; Vural S; Yildirmak Y; Emecen M; Erdem E; Kebudi R
    Pediatr Blood Cancer; 2012 Apr; 58(4):579-83. PubMed ID: 21674768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
    Aamir M; Abrol P; Sharma D; Punia H
    Trop Doct; 2016 Jul; 46(3):142-8. PubMed ID: 26612093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
    Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
    Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors.
    Demirkaya M; Celebi S; Sevinir B; Hacımustafaoglu M
    Pediatr Hematol Oncol; 2013 Mar; 30(2):141-8. PubMed ID: 23301757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
    Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
    J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
    Böhme A; Shah PM; Stille W; Hoelzer D
    Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
    Sato T; Kobayashi R; Yasuda K; Kaneda M; Iguchi A; Kobayashi K
    Pediatr Blood Cancer; 2008 Dec; 51(6):774-7. PubMed ID: 18661495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
    Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
    Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
    Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
    Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with the use of piperacillin-tazobactam in pediatric non-renal solid organ transplantation.
    Wiesmayr S; Stelzmueller I; Mark W; Muehlmann G; Tabarelli W; Tabarelli D; Laesser R; Antretter H; Ladurner R; Zimmerhackl LB; Margreiter R; Guggenbichler JP; Bonatti H
    Pediatr Transplant; 2007 Feb; 11(1):38-48. PubMed ID: 17239122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population.
    Pratt JA; Stricherz MK; Verghese PS; Burke MJ
    Pediatr Blood Cancer; 2014 Feb; 61(2):366-8. PubMed ID: 24038944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
    Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T;
    Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Rizal AM; Nordiah AJ; Jamal R
    Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.